Many studies have verified the breast cancer stem cell line with the CD44+/CD24-/ALDH+ marker, and recently the high expression of aldehyde dehydrogenase (ALDH+) was associated to therapeutic resistance. This evidence concerns the gene CD44 and breast cancer.